{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:36:22Z","timestamp":1792773382097,"version":"4.5.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,9]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>\n                      Pure erythroid leukemia (PEL) is a rare and highly aggressive subtype of acute myeloid leukemia. Herein, a rare case of de novo PEL with rapid progression harboring\n                      <jats:italic toggle=\"yes\">EZH2<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                      frameshift mutations was reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 57-year-old male presented with a 3-week history of pancytopenia and peripheral blasts (9%). He also had a 6-day history of hematemesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>The case was diagnosed as PEL. Bone marrow examination, immunophenotype, gene mutation analysis, and karyotyping confirmed the diagnosis of PEL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Early in his illness, the patient received acid suppression therapy, gastric protection, hemostatic treatment, and transfusions of red blood cell suspension and platelet concentrates at a local hospital. He was later transferred to our hospital, where the diagnosis of PEL was made, and induction chemotherapy was initiated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Following chemotherapy, the patient developed granulocytopenia, severe anemia, and thrombocytopenia. He required multiple transfusions of apheresis platelets and red blood cell suspensions for symptomatic relief. However, due to financial concerns, the patient discontinued treatment and passed away 20 days after starting therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Due to the unclear pathogenesis of PEL and the lack of targeted therapeutic drugs, the prognosis is inferior. Further research into the signaling pathways regulated by the identified mutations and their potential as therapeutic targets is essential to improve the prognosis of this aggressive form of leukemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000039766","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T21:01:04Z","timestamp":1747083664000},"page":"e39766","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["De novo pure erythroid leukemia with rapid progression harboring EZH2 and TP53 frameshift mutations: A case Report"],"prefix":"10.1097","volume":"104","author":[{"given":"Huanhuan","family":"Qin","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8232-1569","authenticated-orcid":false,"given":"Kun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261023","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"R2-20261023","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41408-022-00746-x","article-title":"Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases.","volume":"12","author":"Reichard","year":"2022","journal-title":"Blood Cancer J"},{"key":"R3-20261023","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/modpathol.2010.194","article-title":"Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification.","volume":"24","author":"Liu","year":"2011","journal-title":"Mod Pathol"},{"key":"R4-20261023","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood-2016-11-749903","article-title":"More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.","volume":"129","author":"Montalban-Bravo","year":"2017","journal-title":"Blood"},{"key":"R5-20261023","doi-asserted-by":"crossref","first-page":"106860","DOI":"10.1016\/j.leukres.2022.106860","article-title":"Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy.","volume":"118","author":"Tashakori","year":"2022","journal-title":"Leuk Res"},{"key":"R6-20261023","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ajh.24626","article-title":"Pure erythroid leukemia.","volume":"92","author":"Wang","year":"2017","journal-title":"Am J Hematol"},{"key":"R7-20261023","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.path.2013.08.006","article-title":"Erythroleukemia and its differential diagnosis.","volume":"6","author":"Hasserjian","year":"2013","journal-title":"Surg Pathol Clin"},{"key":"R8-20261023","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/his.13207","article-title":"Acute leukaemia with a pure erythroid phenotype: under-recognized morphological and cytogenetic signatures associated universally with primary refractory disease and a dismal clinical outcome.","volume":"71","author":"Park","year":"2017","journal-title":"Histopathology"},{"key":"R9-20261023","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.5858\/2009-0350-RA.1","article-title":"Acute erythroid leukemia.","volume":"134","author":"Zuo","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"R10-20261023","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms.","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"R11-20261023","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12308-020-00431-7","article-title":"P53 immunohistochemistry discriminates between pure erythroid leukemia and reactive erythroid hyperplasia.","volume":"14","author":"Alexandres","year":"2021","journal-title":"J Hematop"},{"key":"R12-20261023","first-page":"2245","article-title":"The NFIA-ETO2 fusion blocks erythroid maturation and induces pure erythroid leukemia in cooperation with mutant TP53.","volume":"141","author":"Piqu\u00e9-Borr\u00e0s","year":"2023","journal-title":"Blood"},{"key":"R13-20261023","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3324\/haematol.2021.280487","article-title":"Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases.","volume":"107","author":"Fang","year":"2022","journal-title":"Haematologica"},{"key":"R14-20261023","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41375-018-0159-0","article-title":"ASXL1\/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF.","volume":"33","author":"Triviai","year":"2019","journal-title":"Leukemia"},{"key":"R15-20261023","first-page":"738","article-title":"The prognosis and cytogenetic characteristics of acute erythroid leukemia: a report of 55 cases.","volume":"45","author":"Liu","year":"2006","journal-title":"Zhonghua Nei Ke Za Zhi"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000039766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:01:25Z","timestamp":1792767685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000039766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":15,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039766","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,9]]}}}